BioNexus Gene Lab Corp Operating Income Loss

• BioNexus Gene Lab Corp showed an increase of +39.3% in Operating Income Loss from 2023 to 2024.
• This data is from BioNexus Gene Lab Corp's annual report (Form 10-K), filed with the SEC on April 15, 2025.
• XBRL data for this metric is available from 2018 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2018 to 2024), BioNexus Gene Lab Corp's Operating Income Loss has declined by 2,727.2%.
• Historical annual values: Fiscal year 2024: -$1.57 million | Fiscal year 2023: -$2.59 million | Fiscal year 2022: -$291.2 thousand | Fiscal year 2021: $1.06 million | Fiscal year 2020: $1.27 million | Fiscal year 2019: -$275.7 thousand | Fiscal year 2018: $59.9 thousand.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026